Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs.

Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK.

Am J Cancer Res. 2019 Aug 1;9(8):1734-1745. eCollection 2019.

2.

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.

Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D.

Cancer Res. 2019 Oct 1;79(19):5088-5101. doi: 10.1158/0008-5472.CAN-19-0325. Epub 2019 Aug 15.

PMID:
31416846
3.

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.

Dong J, Park SY, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, Henry V, Piao Y, Tiao N, Brunell D, Stephan C, Verhaak R, Sulman E, Balasubramaniyan V, de Groot JF.

Oncotarget. 2018 Jan 8;9(12):10497-10509. doi: 10.18632/oncotarget.24041. eCollection 2018 Feb 13.

4.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2018 Jan 8;33(1):152. doi: 10.1016/j.ccell.2017.12.012. No abstract available.

5.

TumorFusions: an integrative resource for cancer-associated transcript fusions.

Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, Verhaak RGW.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1144-D1149. doi: 10.1093/nar/gkx1018.

6.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):152.

7.

Revealing protein networks and gene-drug connectivity in cancer from direct information.

Jiang XL, Martinez-Ledesma E, Morcos F.

Sci Rep. 2017 Jun 16;7(1):3739. doi: 10.1038/s41598-017-04001-3.

8.

Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.

Fiziev P, Akdemir KC, Miller JP, Keung EZ, Samant NS, Sharma S, Natale CA, Terranova CJ, Maitituoheti M, Amin SB, Martinez-Ledesma E, Dhamdhere M, Axelrad JB, Shah A, Cheng CS, Mahadeshwar H, Seth S, Barton MC, Protopopov A, Tsai KY, Davies MA, Garcia BA, Amit I, Chin L, Ernst J, Rai K.

Cell Rep. 2017 Apr 25;19(4):875-889. doi: 10.1016/j.celrep.2017.03.078.

9.

Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RGW.

Neuro Oncol. 2017 Jun 1;19(6):786-795. doi: 10.1093/neuonc/now285.

10.

Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions.

Treviño V, Martínez-Ledesma E, Tamez-Peña J.

Sci Rep. 2017 Feb 27;7:43350. doi: 10.1038/srep43350.

11.

Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.

Schulze Heuling E, Knab F, Radke J, Eskilsson E, Martinez-Ledesma E, Koch A, Czabanka M, Dieterich C, Verhaak RG, Harms C, Euskirchen P.

Mol Cancer Res. 2017 May;15(5):532-540. doi: 10.1158/1541-7786.MCR-16-0322. Epub 2017 Feb 1.

12.

Systematic analysis of telomere length and somatic alterations in 31 cancer types.

Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang Q, Lichtenberg T, Hu J, Zhang J, Zheng S, Verhaak RG.

Nat Genet. 2017 Mar;49(3):349-357. doi: 10.1038/ng.3781. Epub 2017 Jan 30.

13.

Integration and comparison of different genomic data for outcome prediction in cancer.

Gómez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Palacios-Corona R, Trevino V.

BioData Min. 2015 Oct 29;8:32. doi: 10.1186/s13040-015-0065-1. eCollection 2015.

14.

Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm.

Martinez-Ledesma E, Verhaak RG, Treviño V.

Sci Rep. 2015 Jul 23;5:11966. doi: 10.1038/srep11966.

15.

Seek and destroy: relating cancer drivers to therapies.

Martinez-Ledesma E, de Groot JF, Verhaak RG.

Cancer Cell. 2015 Mar 9;27(3):319-21. doi: 10.1016/j.ccell.2015.02.011.

16.

SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis.

Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A, Tamez-Peña JG, Treviño V.

PLoS One. 2013 Sep 16;8(9):e74250. doi: 10.1371/journal.pone.0074250. eCollection 2013.

Supplemental Content

Loading ...
Support Center